Table 3:
Description of codes related to research integrity
| Code Name | Description | Total Number of Times Coded in Transcripts | Number of Researchers Discussing this Issue |
|---|---|---|---|
| Limitations in research design | Modifications and allowances in research design due to limitations that exist because of Covid-19 or did not exist prior to Covid-19. Limitations may include smaller sample size, lack of randomization, use of unvalidated end points, or other similar limitations made in research design. | 52 | 31 |
| Publication | Discussion regarding the publication process and its impact on science, including: rushed publication, retraction, poor quality of publication, accessibility of published work and availability of research. | 66 | 31 |
| Duplication | Researchers both inside and outside institution simultaneously completing similar or identical research studies, either with or without knowledge that others are also doing so. | 28 | 24 |
| Research Pipeline | The standard process in which research is conducted from start to finish as required by the FDA for approval. Example: biomedical -> pre-clinical -> clinical phase I, II, III. | 34 | 27 |